نتائج البحث - "Antonio Llombart-Cussac"

61

Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease

المؤلفون: Fabrice André, Seock-Ah Im, Patrick Neven, Richard D Baird, Johannes Ettl, Matthew P Goetz, Erika Hamilton, Hiroji Iwata, Zefei Jiang, Anil Abraham Joy, Vincent Haddad, Andrew Walding, Manuel Selvi Miralles, Cynthia Huang Bartlett, Antonio Llombart-Cussac

المصدر: Cancer Research. 82:OT2-11

مصطلحات موضوعية: Cancer Research, Oncology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::879f6baf624d5d75a60498e5886da78a
https://doi.org/10.1158/1538-7445.sabcs21-ot2-11-06

62

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials

المؤلفون: Aranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, Paolo Nuciforo, Naim U. Rashid, Karla V. Ballman, Jordan D. Campbell, Katherine A. Hoadley, Patricia A. Spears, Laia Pare, Fara Brasó-Maristany, Nuria Chic, Ian Krop, Ann Partridge, Javier Cortés, Antonio Llombart-Cussac, Aleix Prat, Charles M. Perou, Lisa A. Carey

المساهمون: Institut Català de la Salut, [Fernandez-Martinez A] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill. Department of Genetics, University of North Carolina, Chapel Hill. [Pascual T] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill. Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. SOLTI Breast Cancer Cooperative Group, Barcelona, Spain. [Singh B] Department of Pathology, White Plains Hospital, White Plains, New York. [Nuciforo P] Molecular Oncology Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rashid NU] Department of Biostatistics, University of North Carolina, Chapel Hill. [Ballman KV] Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Mama - Càncer - Prognosi, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Cancer Research, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos infiltrantes de tumor [ANATOMÍA], Investigative Techniques::Genetic Techniques::Gene Expression Profiling [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::Lymphocytes, Tumor-Infiltrating [ANATOMY], Expressió gènica, Limfòcits, técnicas de investigación::técnicas genéticas::perfiles de expresión génica [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Oncology, Mama - Càncer - Tractament, Diagnosis::Prognosis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf9a35b3b0374e7c5bc9c18bf13b2c82
https://pubmed.ncbi.nlm.nih.gov/36602784

63

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

المساهمون: Institut Català de la Salut, [Di Cosimo S] ndazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ, USA. [Pérez-García JM] International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ, USA. [Bellet M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Dalenc F] Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Department of Medical Oncology, Toulouse, France. [Gil Gil MJ] Institut Català d’Oncologia, Breast Cancer Unit and Medical Oncology Department, IDIBELL, L’Hospitalet, Barcelona, Spain. [Ruiz Borrego M] Hospital Universitario Virgen del Rocío, Medical Oncology Department, Seville, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Endocrine therapy, Cancer Research, Neutropenia, palbociclib, Receptor, ErbB-2, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], venous thromboembolism, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Interstitial lung disease, Breast Neoplasms, Palbociclib, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Quimioteràpia combinada, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Antineoplastic Combined Chemotherapy Protocols, neutropenia, Humans, Other subheadings::/therapeutic use [Other subheadings], Fulvestrant, advanced breast cancer, interstitial lung disease, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Otros calificadores::/uso terapéutico [Otros calificadores], endocrine therapy, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], pneumonitis, Oncology, Receptors, Estrogen, Mama - Càncer - Tractament, Letrozole, Advanced breast cancer, Female, Pneumonitis, Pulmonary Embolism, Venous thromboembolism

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e94856ca3e331564bbf534f081808407
https://academic.oup.com/oncolo/article-pdf/28/1/23/48837357/oyac205.pdf

64

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

المساهمون: Institut Català de la Salut, [Pascual T, Villagrasa P, Paré L] SOLTI Breast Cancer Research Group, Barcelona, Spain. [Oliveira M] SOLTI Breast Cancer Research Group, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Breast Cancer Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ortega V] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Breast Cancer Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Bermejo B] Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain. [Nuciforo P] Molecular Oncology Lab, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rubio IT] Breast Cancer Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Cortés J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: npj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
Scientia
NPJ Breast Cancer

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Disease, Predictive markers, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Article, chemistry.chemical_compound, Breast cancer, Internal medicine, Medicine, Pharmacology (medical), Radiology, Nuclear Medicine and imaging, Stage (cooking), RC254-282, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], business.industry, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Odds ratio, Translational research, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine.disease, Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], chemistry, Mama - Càncer - Tractament, Cohort, Avaluació de resultats (Assistència sanitària), Biomarker (medicine), terapéutica::tratamiento combinado::tratamiento neoadyuvante [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], business, Eribulin